Compare GPK & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPK | IMNM |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2007 | 2020 |
| Metric | GPK | IMNM |
|---|---|---|
| Price | $9.39 | $24.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $13.08 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 3.9M | 951.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,617,000,000.00 | $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | $1,127.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.79 | $8.93 |
| 52 Week High | $21.24 | $30.06 |
| Indicator | GPK | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 27.61 | 42.00 |
| Support Level | $9.09 | $19.28 |
| Resistance Level | $10.02 | $27.14 |
| Average True Range (ATR) | 0.41 | 1.08 |
| MACD | -0.24 | -0.48 |
| Stochastic Oscillator | 1.24 | 1.54 |
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Americas Paperboard Packaging, and International Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company operates in Americas, Europe and Asia Pacific regions.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.